CMS raised concerns with the new-technology add-on payment applications for all six fiscal year 2016 device applicants in the agency’s hospital inpatient proposed rule, including for drug-coated balloons, Boston Scientific Corp.’s Watchman left-atrial appendage stroke device and other cardiovascular and orthopedic products.
CMS Raises Concerns With New-Technology Payment Candidates
Boston Scientific’s Watchman stroke device, Medtronic and Bard’s drug-coated balloons, Cardiovascular Systems atherectomy systems and two other devices each come in for criticism in the Medicare agency’s consideration of the next round of inpatient bonus payments for new technologies.